Abstract:Background: Grb2 (Growth factor receptor-bound protein 2) is a key adaptor protein in maintaining the ERK activity via linking Sos1 (Son of sevenless homolog 1) or other proteins to activated RTKs, such as EGFR. Currently, little knowledge is available concerning the post-translational modification (PTM) of Grb2 except for its phosphorylation. Since emerging evidences have highlighted the importance of SUMOylation (Small ubiquitin-related modifier), a reversible PTM, in modulating protein functions, we wondered if Grb2 could be SUMOylated and thereby influences its functions especially involved in the Ras/MEK/ERK pathway. Methods: SUMOylation of Grb2 was analyzed with the in vivo SUMOylation assay using the Ni2+-NTA affinity pulldown and the in vitro E.coli-based SUMOylation assay. To test the ERK activity and cell transformation, the murine fibroblast cell line NIH/3T3 and the murine colon cancer cell line CMT-93 were used for the experiments including Grb2 knockdown, ectopic re-expression, cell transformation and migration. Immunoprecipitation (IP) was employed for seeking proteins that interact with SUMO modified Grb2. Xenograft tumor model in mice was conducted to verify that Grb2 SUMOylation regulated tumorigenesis in vivo. Results: Grb2 can be SUMOylated by SUMO1 at lysine 56 (K56), which is located in the linker region between the N-terminal SH3 domain and the SH2 domain. Knockdown of Grb2 reduced the ERK activity and suppressed cell motility and tumorigenesis in vitro and in vivo, which were all rescued by stable ectopic re-expression of wild-type Grb2 but not the mutant Grb2K56R. Furthermore, Grb2 SUMOylation at K56 increased the formation of Grb2-Sos1 complex, which sequentially leads to the activation of Ras/MEK/MAPK pathway. Conclusions: Our results provide evidences that Grb2 is SUMOylated in vivo and this modification enhances ERK activities via increasing the formation of Grb2-Sos1 complex, and may consequently promote cell motility, transformation and tumorigenesis.

SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1

Ribosomal Protein S6 Kinase (RSK)-2 As a Central Effector Molecule in RON Receptor Tyrosine Kinase Mediated Epithelial to Mesenchymal Transition Induced by Macrophage-Stimulating Protein

SUMOylation mediates the disassembly of the Smad4 nuclear export complex via RanGAP1 in KELOIDS

Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development.

Sumoylation Enhances the Activity of the TGF-β/SMAD and HIF-1 Signaling Pathways in Keloids

SUMOylation of Smad2 mediates TGF-β-regulated endothelial-mesenchymal transition

SUMOylation involves in β-arrestin-2-dependent metabolic regulation in breast cancer cell

SUMOylation of Rb Enhances Its Binding with CDK2 and Phosphorylation at Early G1 Phase

Grb2 Phosphorylation Antagonizes EGFR-driven Ras Activation by Interfering with Condensate Assembly

SUMOylation at K707 of DGCR8 Controls Direct Function of Primary Microrna.

Sumoylation of EphB1 Suppresses Neuroblastoma Tumorigenesis Via Inhibiting PKCγ Activation

Different molecular recognition by three domains of the full-length GRB2 to SOS1 proline-rich motifs and EGFR phosphorylated sites

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

Targeting Grb2 SH3 Domains with Affimer Proteins Provides Novel Insights into Ras Signalling Modulation

SUMOylation is Essential for Sirt2 Tumor-Suppressor Function in Neuroblastoma

O-GlcNAcylation of MEK2 Promotes the Proliferation and Migration of Breast Cancer Cells.

Hyper-SUMOylation of ERG Is Essential for the Progression of Acute Myeloid Leukemia

The Configuration of GRB2 in Protein Interaction and Signal Transduction

Unveiling the impact of SUMOylation at K298 site of heat shock factor 1 on glioblastoma malignant progression

SUMO Modifies GβL and Mediates mTOR Signaling